MedTrace Logo

Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

NCT05199337 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a single arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis.

Conditions

  • Amyloidosis
  • AL Amyloidosis

Interventions

DRUG

ZN-d5

ZN-d5 will be administered orally

Sponsors & Collaborators

  • K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Affairs · K-Group Alpha subsidiary of Zentalis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2024-02-14
Completion
2024-02-14
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Cyprus
  • Greece
  • Israel
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05199337 on ClinicalTrials.gov